Non-Viral Engineered CAR-T Cells for Safe and Specific Stem Cell Transplant Conditioning

被引：0
|
作者：
Timberlake, Nina D. [1 ]
Koechlein, Claire S. [1 ]
Richter, Maximilian [1 ]
Wang, Xinxin [1 ]
Chen, Natalie [1 ]
Cam, Nicholas [1 ]
Codde, Rebecca [1 ]
Tan, Yening [1 ]
Avanesyan, Armenuhi [1 ]
Hermann, Kip [2 ]
Ostertag, Eric M. [1 ]
Shedlock, Devon J. [1 ]
Down, Julian [1 ]
机构：
[1] Poseida Therapeut, San Diego, CA USA
[2] Scripps Res Inst, San Diego, CA USA
来源：
MOLECULAR THERAPY | 2018年 / 26卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
505
引用
收藏
页码：236 / 237
页数：2
相关论文
共 50 条
  • [21] Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment
    Arai, Yasuyuki
    Choi, Uimook
    Corsino, Cristina I.
    Koontz, Sherry M.
    Tajima, Masaki
    Sweeney, Colin L.
    Black, Mary A.
    Feldman, Steven A.
    Dinauer, Mary C.
    Malech, Harry L.
    MOLECULAR THERAPY, 2018, 26 (05) : 1181 - 1197
  • [22] Epitope Engineered Hematopoietic Stem and Progenitor Cells to Enable CAR-T Cell Immunotherapy for Acute Myeloid Leukemia
    Casirati, Gabriele
    Cosentino, Andrea
    Mucci, Adele
    Sereni, Lucia
    Cinella, Vincenzo
    Brendel, Christian
    Rambaldi, Alessandro
    Ritz, Jerome
    Armstrong, Scott A.
    Genovese, Pietro
    MOLECULAR THERAPY, 2022, 30 (04) : 162 - 163
  • [23] Current Non-Viral-Based Strategies to Manufacture CAR-T Cells
    Gehrke, Leon
    Goncalves, Vasco Dos Reis
    Andrae, Dominik
    Rasko, Tamas
    Ho, Patrick
    Einsele, Hermann
    Hudecek, Michael
    Friedel, Sabrina R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (24)
  • [24] Anti-c-kit CAR-T Cells Afford Effective Eradication of Human AML and Normal Hematopoietic Cells in a Preclinical Model of Safer Non-Genotoxic Stem Cell Transplant Conditioning
    Timberlake, Nina
    MOLECULAR THERAPY, 2021, 29 (04) : 347 - 347
  • [25] Development of non-viral site-specific integrated CAR-T technology and its application in clinical treatment of relapsed/refractory B-cell non-Hodgkin lymphoma
    Wei, Yanyan
    Jiang, Wenzheng
    CHINESE SCIENCE BULLETIN-CHINESE, 2022, 67 (34): : 4036 - 4038
  • [26] Developing off-the-shelf CAR T-cells: Non-viral and site-specific knockout of TCR and knock-in of CAR
    Mach, Melanie
    Gowrishankar, Kavitha
    Bishop, David
    Micklethwaite, Kenneth
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 38 - 39
  • [27] Production of Human CRISPR-Engineered CAR-T Cells
    Agarwal, Sangya
    Wellhausen, Nils
    Levine, Bruce L.
    June, Carl H.
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (169):
  • [28] Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers
    Chinsuwan, Thanyavi
    Hirabayashi, Koichi
    Mishima, Shuji
    Hasegawa, Aiko
    Tanaka, Miyuki
    Mochizuki, Hidemi
    Shimoi, Akihito
    Murakami, Takashi
    Yagyu, Shigeki
    Shimizu, Kimihiro
    Nakazawa, Yozo
    MOLECULAR THERAPY ONCOLYTICS, 2023, 31
  • [29] Non-viral, precisely engineered immune cells tested in lymphoma
    Hu, Yongxian
    Zhang, Jiqin
    Eyquem, Justin
    NATURE, 2022,
  • [30] CAR-T cells to deliver engineered peptide antigens and reprogram antigen specific T cell responses against solid tumors.
    Lee, Daniel
    Minn, Andy J.
    Johnson, Lexus R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345